Skip to main content

11 Result(s)

within Lidan Yi Remove this filter

and

  1. No Access

    Article

    Comparison Between Sotorasib with Docetaxel for the Treatment of Chinese Patients with Previously Treated NSCLC with KRASG12C Mutation: A Cost-Effectiveness Analysis to Inform Drug Pricing

    This study sought to investigate the affordable price of sotorasib among patients with previously treated advanced KRASG12C-mutant non-small cell lung cancer (NSCLC) through a cost-effectiveness analysis from ...

    Lidan Yi, **aohui Zeng, Zhen Zhou, Qiao Liu in Advances in Therapy (2024)

  2. No Access

    Article

    Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study

    A new gastric cancer screening scoring system (NGCS) strategy was recommended for the early gastric cancer (GC) screening process in China. The current study aimed to assess the clinical benefits and the cost ...

    Shuxia Qin, Xuehong Wang, Sini Li, Chongqing Tan, **aohui Zeng… in PharmacoEconomics (2022)

  3. No Access

    Article

    Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis

    Biologic disease-modifying antirheumatic drugs (bDMARDs) are recommended to be added in sequentially in the treatment of moderate-to-severe rheumatoid arthritis (RA). All these drugs, however, are substantiall...

    Chongqing Tan, **a Luo, Sini Li, Lidan Yi, **aohui Zeng… in Clinical Rheumatology (2022)

  4. No Access

    Article

    Cost-Effectiveness of Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma in the United States

    The JAVELIN Bladder 100 trial showed that maintenance avelumab therapy after chemotherapy improved the survival of patients with advanced or metastatic urothelial carcinoma. We analyzed the cost-effectiveness ...

    Ye Peng, Zhihua She, Liubao Peng, Qiao Liu, Lidan Yi, **a Luo… in Advances in Therapy (2021)

  5. No Access

    Article

    Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer

    The effectiveness of nivolumab plus ipilimumab with two cycles of chemotherapy (NIC) for advanced non-small cell lung cancer (NSCLC) has been demonstrated. We aimed to evaluate the cost-effectiveness of NIC fo...

    Ye Peng, **aohui Zeng, Liubao Peng, Qiao Liu, Lidan Yi, **a Luo… in Advances in Therapy (2021)

  6. No Access

    Article

    Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer

    The IMvigor130 trial found that atezolizumab plus platinum-based chemotherapy (atezolizumab group) as first-line therapy prolonged progression-free survival (PFS) in patients with metastatic urothelial cancer ...

    Shuxia Qin, Lidan Yi, Sini Li, Chongqing Tan, **aohui Zeng… in Advances in Therapy (2021)

  7. No Access

    Article

    Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma

    The ALCYONE trial found that daratumumab in combination with bortezomib, melphalan, and prednisone (D-VMP) can significantly improve progression-free survival (PFS) and overall survival (OS) for patients with ...

    **aohui Zeng, Qiao Liu, Liubao Peng, Ye Peng, Lidan Yi, **a Luo… in Advances in Therapy (2021)

  8. No Access

    Article

    First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis

    The IMpower110 trial evaluated the efficacy and safety of atezolizumab in previously untreated patients with metastatic non-small cell lung cancer (NSCLC). Due to the high cost of immunity inhibitors, it is ne...

    Ye Peng, **aohui Zeng, Liubao Peng, Qiao Liu, Lidan Yi, **a Luo… in Advances in Therapy (2021)

  9. No Access

    Article

    Tofacitinib in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in China: A Cost-Effectiveness Analysis Based on a Map** Algorithm Derived from a Chinese Population

    To estimate the cost-effectiveness of tofacitinib for patients with moderate-to-severe rheumatoid arthritis (RA) who failed conventional synthetic disease-modifying antirheumatic drugs from the Chinese healthc...

    Chongqing Tan, Sini Li, Lidan Yi, **aohui Zeng, Liubao Peng… in Advances in Therapy (2021)

  10. Article

    Open Access

    Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis

    The economic assessment of immuno-oncology agents in Chinese patients is limited despite a need for new therapies. Nivolumab is the first immune checkpoint inhibitor approved for the second-line treatment of n...

    Qiao Liu, **a Luo, Liubao Peng, Lidan Yi, **aomin Wan… in Clinical Drug Investigation (2020)

    Download PDF (863 KB) View Article

  11. No Access

    Article

    Model-Based Economic Evaluation of Ceritinib and Platinum-Based Chemotherapy as First-Line Treatments for Advanced Non-Small Cell Lung Cancer in China

    A trial-based assessment was completed to evaluate the cost-effectiveness of ceritinib as a first-line treatment for advanced non-small cell lung cancer (NSCLC) with rearrangement of anaplastic lymphoma kinase.

    Ye Peng, Fang Ma, Chongqing Tan, **aomin Wan, Lidan Yi, Liubao Peng… in Advances in Therapy (2019)